International Journal of Rheumatic Diseases
© Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
Edited By: Debashish Danda
Impact Factor: 0.807
ISI Journal Citation Reports © Ranking: 2011: 24/29 (Rheumatology)
Online ISSN: 1756-185X
NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor. The Editorial Board reserves the right to refuse any material for publication. Final acceptance or rejection rests with the Editorial Board.
Prior to the submission of a manuscript, authors should familiarize themselves and comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals relating to:
Conflict of interest
Protection of patients’ rights to privacy
Redundant or duplicate publication
Sponsorship, authorship and accountability
Authors must also state within the Methods section of their article that:
the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the World Medical Association’s Declaration of Helsinki
informed consent has been obtained for all investigations on human subjects (and patient anonymity has been preserved)
any experiments involving animals conform to relevant national or institutional guidelines for animal usage in research.
Failure to comply with these requirements may lead to automatic rejection of the submitted manuscript.
SUBMISSION OF MANUSCRIPTS
All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor or the Publisher reserves the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.
Covering letter Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the covering letter. Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). All investigations on human subjects must include a statement that the subject gave informed consent and patient anonymity should be preserved. Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research. Authors should declare any financial support or relationships that may pose conflict of interest.
Submission APLAR uses an electronic submission process. Please enter the website: mc.manuscriptcentral.com/aplar. If you are currently a reviewer for our Journal please email email@example.com for your Login ID and Password. If you are new to the Journal please create an author account for yourself by clicking the link on the top right hand corner of the webpage. After logging in you will be able to submit your paper by following the steps. When uploading your manuscript please note that all figures should be uploaded in separate eps or tiff files (See Figures section below). Please email firstname.lastname@example.org if you have any difficulties.
Copyright Manuscripts will be reviewed for possible publication with the understanding that neither the article nor any part of it has been submitted for publication or will be submitted for publication elsewhere. If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below: CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.SPECIFICS FOR MANUSCRIPT SUBMISSION BY ARTICLE TYPE
Editorials usually provide commentary on an article in the issue of the Journal. Editorials are commissioned by the Editor-in-Chief, though unsolicited editorials may be considered.
Reviews are comprehensive analyses of specific topics either basic or clinical. They are submitted upon invitation by the Editors. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance. They should contain a maximum of 4000 words (excluding Abstract, Tables, and References).
Original Articles should reflect original work that embodies scientific excellence in rheumatology and advances in clinical research. They should contain a maximum of 4000 words (excluding Abstract, Tables, and References) and must contain a structured Abstract of 250 words or less together with a list of key words and up to 6 tables or figures and a maximum of 50 references. Divide the Abstract with the headings: Aim, Method, Results, Conclusion.
Novel Hypothesis offers the researchers an opportunity to raise aclinical or experimentalhypothesis,which is based on Biological basis, but yet to be proven. The text is limited to a maximum of 1,000 words including abstract but excluding references, tables and figures. No abstract is required.
APLAR Grand Round Case
APLAR Grand Round Case an exceptional case with novel message and in depth work up and educative discussion, the text is limited to 1500 words.
Postgraduate Quiz can include a number of images of rare, classical or interesting case, each image should be accompanied by a brief summary of the case (if appropriate) and question(s) that are designed to test the participant's knowledge. The answer(s) should follow separately and should include a brief description of the diagnostic features of the image and the key learning points. The text is limited to 1000 words.
Rheumatology News & Views from APLAR Region
They can be political, social, economic, cultural and other regional issues and comments relevant to the Rheumatology in the APLAR region
Expert Comments on Recent Publications Expert Comments on Recent Publications are solicited by the Editor-in-Chief. Top expert(s) will be invited to summarise top 10 publications within the recent past 2 months with relevant learning points. The text is limited to 1500 words.
Correspondences discuss a recent article published in the International Journal of Rheumatic Diseases(IJRD). Correspondences being considered for publication will be sent to the authors of the IJRD article, who will be given the opportunity to reply. Interesting case reports may be published under this category. They should be no more than 1000 words with a maximum of 10 references and up to 2 figures or tables. No Abstract or key words are required.
Milestones in Science, Art and Commerce of Rheumatology This column reviews the landmark developments of rheumatology, including write up about a great scientist in Rheumatology or exemplary patients. The text is limited to 1500 words.
Letter from the Editor
Letter from the Editor are the Editor’s opinion on any issue relevant to the journal. It may be merged with the Editorial.
GENERAL INFORMATION FOR AUTHORS FOR ALL ARTICLE TYPES
Submissions should be doubled-spaced. The top, bottom and side margins should be 30 mm. (Manuscript central numbers pages automatically) Indent new paragraphs. Turn the hyphenation option off, including only those hyphens that are essential to the meaning.
Style Manuscripts should follow the style of the Vancouver agreement detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as presented in JAMA 1997; 277: 927–34. The journal uses US spelling and authors should therefore follow the latest edition of Merriam–Webster’s Collegiate Dictionary. All measurements must be given in SI units as outlined in the latest edition of Units, Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors (Royal Society of Medicine Press, London). Abbreviations should be used sparingly and only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. Drugs should be referred to by their generic names, rather than brand names.
• Do not use the carriage return (enter) at the end of lines within a paragraph.
• Specify any special characters used to represent non-keyboard characters.
• Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for b (Greek beta).
• Use a tab, not spaces, to separate data points in tables.
• If you use a table editor function, ensure that each data point is contained within a unique cell; i.e. do not use carriage returns within cells.
• Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
Title page The title page should contain (i) the title of the paper (do not use abbreviations in title), (ii) the full names of the authors and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript, proofs and requests for offprints should be sent. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified. The title should be short, informative and contain the major key words. A short running title (less than 40 characters, including spaces) should also be provided.
Acknowledgments The source of financial grants and other funding should be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not allowed.
References The Vancouver system of referencing should be used. In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited only in tables or figure legends, number them according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in order of appearance in the text. Cite the names of all authors when there are six or less; when seven or more list the first three followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should appear in the text only. References should be listed in the following form.
Journal article: Needleman P, Isakson PC (1997) The discovery and function of COX-2. J Rheumatol 24,6–7.
Book: Munthe E (ed.) The Care of Rheumatic Children. European League Against Rheumatism, Basel, Switzerland.
Chapter in a book: Croft P (1993) Soft tissue rheumatism. In: AJ Silman, MC Hochberg (eds) Epidemiology of the Rheumatic Diseases, pp. 375–421. Oxford University Press, Oxford.
Tables Tables should be self-contained and complement, but not duplicate, information contained in the text. Tables should be numbered consecutively in Arabic numerals. Each table should be presented on a separate page with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. The table and its legend/footnotes should be understandable without reference to the text.
Figures All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Image files should be supplied as high resolution (at least 300 d.p.i.) files, saved as .eps or .tif format and uploaded separately in your Manuscript Central submission with each file labelled “Figure 1, Figure 2” etc. When uploading your documents into Manuscript Central please note that the “Supplemental File” file designation is not seen by reviewers.
Color figures A charge of US$530 for the first three color figures and US$265 for each extra color figure thereafter will be charged to the author.
Figure legends Legends should be self-explanatory and placed at the end of your main document. The legend should incorporate definitions of any symbols used and all abbreviations and units of measurement should be explained so that the figure and its legend are understandable without reference to the text. (State copyright authorization if figures have been reproduced from another source.)
It is essential that corresponding authors supply an email address to which correspondence can be emailed while their article is in production. Word files of edited articles will be sent for checking via email, and should be returned to the Publisher. It is essential that these files are checked carefully, as the cost of changes made at a later stage may be charged to the author. Full instructions on how to correct and return the file will be attached to the email. Notification of the URL from where to download a Portable Document Format (PDF) typeset page proof, associated forms and further instructions will be sent by email to the corresponding author. The purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the essential correction of errors are unacceptable at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated; otherwise, it may be signed off on by the Editor or held over to the next issue.
Free access to the final PDF offprint of your article will be available via author services. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.
BLACKWELL JOURNALS ONLINE
Visit the International Journal of Rheumatic Diseases home page at http:// www.blackwellpublishing.com/ijrd for more information, and Wiley-Blackwell’s web pages for submission guidelines and digital graphics standards at http://www.blackwellpublishing.com/bauthor/ journal.asp and http://www.blackwellpublishing.com/bauthor/ digill.asp. International Journal of Rheumatic Diseases is also available online via Wiley Interscience at www.interscience.wiley.com.